Blueprint Medicines to Present at JMP Securities Life Sciences Private Company Conference
October 14, 2014 08:30 ET
|
Blueprint Medicines
CAMBRIDGE, Mass., Oct. 14, 2014 (GLOBE NEWSWIRE) -- Blueprint Medicines today announced that Kyle Kuvalanka, chief business officer, will present a company overview at the JMP Securities Life Sciences...
Blueprint Medicines to Present at 13th Annual BIO Investor Forum
September 30, 2014 08:30 ET
|
Blueprint Medicines
CAMBRIDGE, Mass., Sept. 30, 2014 (GLOBE NEWSWIRE) -- Blueprint Medicines today announced that Kyle Kuvalanka, chief business officer, will present a company overview at the 13th Annual BIO Investor...
Blueprint Medicines to Participate in Morgan Stanley Global Healthcare Conference 2014
September 09, 2014 08:30 ET
|
Blueprint Medicines
CAMBRIDGE, Mass., Sept. 9, 2014 (GLOBE NEWSWIRE) -- Blueprint Medicines today announced that members of the Company's senior management team will participate in the Morgan Stanley Global Healthcare...
Blueprint Medicines to Present at Wedbush 2014 Life Sciences Management Access Conference
August 06, 2014 08:30 ET
|
Blueprint Medicines
CAMBRIDGE, Mass., Aug. 6, 2014 (GLOBE NEWSWIRE) -- Blueprint Medicines today announced that members of the Company's senior management team will present at the Wedbush 2014 Life Sciences Management...
Blueprint Medicines to Present at JMP Securities Healthcare Conference
June 20, 2014 08:30 ET
|
Blueprint Medicines
CAMBRIDGE, Mass., June 20, 2014 (GLOBE NEWSWIRE) -- Blueprint Medicines today announced that Kyle Kuvalanka, chief business officer, will present a company overview at the JMP Securities Healthcare...
Blueprint Medicines Presents Positive Data on First Selective FGFR4 Inhibitor
April 07, 2014 08:39 ET
|
Blueprint Medicines
CAMBRIDGE, Mass., April 7, 2014 (GLOBE NEWSWIRE) -- Blueprint Medicines today announced that promising preclinical data on its first-in-class selective fibroblast growth factor receptor 4 (FGFR4)...
Blueprint Medicines to Present on the First Isoform Selective FGFR4 Inhibitor at the AACR Annual Meeting 2014
March 24, 2014 16:01 ET
|
Blueprint Medicines
CAMBRIDGE, Mass., March 24, 2014 (GLOBE NEWSWIRE) -- Blueprint Medicines today announced that new data on its first-in-class isoform selective fibroblast growth factor receptor 4 (FGFR4) inhibitor...
Blueprint Medicines to Present at Upcoming Investor Conferences
March 20, 2014 16:01 ET
|
Blueprint Medicines
CAMBRIDGE, Mass, March 20, 2014 (GLOBE NEWSWIRE) -- Blueprint Medicines today announced that members of the Company's senior management team will present at upcoming financial...